• Study Establishes ENPP1 As A Biomarker For Immunotherapy Benefit

    Clinical Research News | Researchers in California have shown that breast cancer patients with RNA expression levels of ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) in the bottom 50th percentile can confidently be treated with Keytruda (pembrolizumab) as well as surgery.

    Mar 7, 2024
  • Five Health Systems Picking Dandelion Health To Advance Clinical AI

    Clinical Research News | If artificial intelligence (AI) is to be as insightful as possible in advancing human health, it is not enough to have a patchwork of out-of-context data from which to draw conclusions. That is unfortunately the current situation and at the cost of lost opportunities to better treat patients, identify early biomarkers of disease, and recognize the right endpoints in clinical trials—not to mention eradicating existing biases against marginalized groups of people.

    Mar 6, 2024
  • Future Looks Bright For Decentralized Clinical Trials

    Clinical Research News | Decentralized clinical trials (DCTs) today are both more fit-for-purpose and business-as-usual than uncertain and unavoidable, as was the case during the height of the COVID-19 pandemic. Among the key challenges with DCTs are keeping sites and patients engaged, dealing with the near-constant inflow of data from digital platforms and wearable devices, and quantifying the value of various decentralized study components.

    Mar 5, 2024
  • Medidata Collaboration to Deploy Vaccine Studies, New CEO at Saama, H1 Updates to AI Toolkit, More

    Clinical Research News | Medidata and Sanofi Vaccines announced a collaboration to harness Medidata eCOA to deploy in vaccine studies; H1 has launched GenosAI Pro, a new addition to its conversational AI toolkit within Trial Landscape platform; and more.

    Feb 29, 2024
  • Follow the Money: First Circular RNA-Based Clinical Assay, Oncology Programs, More

    Clinical Research News | Circular Genomics plans to build and scale commercial operations in preparation for the launch of the world's first circular RNA-based clinical assay; NextPoint Therapeutics will advance the company’s two immuno-oncology clinical programs, NPX267 and NPX887; Accent Therapeutics will use funding to support the advancement of both lead programs—Accent’s first-in-class DHX9 inhibitor and a potentially best-in-class KIF18A inhibitor; and more.

    Feb 28, 2024